Navigation Links
AstraZeneca Expands Prescription Savings Program
Date:7/23/2009

WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today it is expanding its prescription savings program by immediately extending assistance to qualifying patients who have recently lost their jobs, had their incomes reduced, or experienced a change in marital status or family size.

Previously, patients who experienced a change in income or family size had difficulty applying to the program if their W2 statements showed a non-qualifying income. Now, qualifying people who provide documentation of their current income and family size can enroll more easily and receive their AstraZeneca medicines more quickly.

"AstraZeneca is committed to helping patients get the medicines they need," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP. "Our responsibility goes beyond developing medicines to also making them available to those who cannot afford them."

For more than 30 years, AstraZeneca has offered patient assistance programs side-by-side with its medicines. In 2008, AstraZeneca helped more than 440,000 people fill 2.7 million prescriptions resulting in $612 million of savings to patients.

AstraZeneca provides free or low-cost medicines to patients through its AZ&Me(TM) Prescription Savings programs in three ways:

  • AZ&Me(TM) Prescription Savings program for people without insurance: AstraZeneca provides AstraZeneca medicines at no cost to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four who make up to $60,000 per year.
  • AZ&Me(TM) Prescription Savings program for people with Medicare Part D: AstraZeneca provides low-cost AstraZeneca medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year.
  • AZ&Me(TM) Prescription Savings program for healthcare facilities: AstraZeneca provides AstraZeneca medicines at no cost to qualifying non-profit healthcare facilities, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the AstraZeneca medicines they need at the same time and place they receive their treatment.

Patients can learn more about the AZ&Me(TM) Prescription Savings program at www.azandme.com or by calling 1-800-AZandMe.

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca Partners With Primary Health Care to Help Iowa Uninsured
2. AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease
3. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
4. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
5. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
6. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
7. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
8. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
9. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
10. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
11. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: